UNSPSC 51292912: Mianserin

This classification denotes a serotonin antagonist and antidepressant agent and adrenergic antagonist with the molecular formula C18H20N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 250PJI13LM, chemically known as 1,2,3,4,10,14b-hexahydro-2-methyldibenzo(c,f)pyrazino(1,2-a)azepine but generally known as mianserin, which bears US NIH Compound Identifier 4184. European Medicines Agency schedules Mianserin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08939MIG.

UNSPSC 51292912 Mianserin is a Commodity code that in recent state and local procurement activity covers pharmaceutical products and drug-related health supplies, though the code's nominal scope and actual purchasing patterns show significant divergence. Seminole County, Florida's recent IFB for naloxone and safe drug deactivation systems—posted June 30, 2026, with a response deadline of July 26, 2023—represents the primary recent activity tagged to this code. The county is procuring 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building. Vendors must include all shipping and delivery costs in their proposals, submit bids electronically through the county's e-Procurement Portal, and meet drug-free workplace certification and E-Verify compliance requirements. The contract carries a two-year initial term with an option for one-year renewal and includes a three-month probationary period allowing termination with or without cause. Insurance requirements include workers' compensation, commercial general liability, and professional liability coverage. The procurement may be funded through FEMA, introducing additional compliance obligations under the Clean Air Act and Federal Water Pollution Control Act.

The source shows limited recent state and local activity under this Commodity code, with only Seminole County, Florida represented in the recent-opportunities block. Geographic spread is narrow—the source supports activity only in Florida. The code demonstrates minimal marketplace activity at the state and local level; this single opportunity centered on health and public-safety supplies suggests potential misalignment between the code's pharmaceutical focus and the actual community health and harm-reduction purchasing underway in practice.